Blog | HemaCare

HemaCare Leukopaks Support Novel Gene Editing Strategy

May 7, 2019 10:07:00 AM / by Nancy Andon, MSc posted in leukopaks, gene editing, hematopoietic stem cells


In an independent publication [1] researchers at UCLA cited using leukopaks obtained from HemaCare in order to investigate a new gene editing method.

The group is researching strategies to treat genetic blood disorders such as sickle cell anemia. While there has been a great deal of research focused on using CRISPR/Cas9 gene therapy to treat these illnesses [2], current strategies for gene editing in hematopoietic stem cells are inefficient, and thus costly.

Read More

HemaCare Immune Cells Facilitate Study on Gene Activation During Stem Cell Development

Jan 15, 2019 10:04:00 AM / by Nancy Andon, MSc posted in genes, hematopoietic stem cells, Stem Cells


A recent independent study cites using HemaCare-sourced immune cells to investigate a protein involved in gene activation during hematopoietic stem cell (HSC) development. [1]

The study, published by scientists at the Yokohama Institute in Japan, is focused on the function of a protein known as RUNX1. The reason RUNX1 is of particular interest is that it’s implicated in the development of a number of different types of cancer, including breast cancer, skin cancer, and acute myeloid leukemia. [2] In the latter case, defects in the gene that codes for the RUNX1 protein disrupt stem cell differentiation. This means that instead of normal development into mature cell types, there is a massive build-up of blast cells in the bone marrow, which is the hallmark of leukemia. Scientists have known since 2001 [3] that the RUNX1 protein is involved in the differentiation of hematopoietic stem cells into mature blood cells. But in order to target RUNX1’s role in cancer development, researchers need a much more in-depth knowledge of exactly how the protein is exerting its function.

Read More

Improving the Efficiency of Clinical Gene Therapy

Jul 23, 2018 10:09:00 AM / by Nancy Andon, MSc posted in engraftment, Gene Therapy, gene editing, hematopoietic stem cells, progenitor cells


An independent study [1] cites using HemaCare-sourced human cord blood, bone marrow, and mobilized peripheral blood as the starting material in a new strategy for more efficient genetic modification of human stem cells.

The study is based at the San Raffaele Telethon Institute for Gene Therapy in Milan, Italy. Researchers there have been looking into ways to make gene transduction, which is used to introduce an edited copy of a human gene into stem cells, more efficient. The new strategy is part of their goal to improve the potency and long-term engraftment of stem cells used for gene therapy in the clinic.

Read More

Stem Cells May Aid ALS Treatment

Jun 4, 2018 10:09:00 AM / by Stacy Matthews Branch, DVM, PhD posted in hematopoietic stem cells, Stem Cells


New research shows the potential regenerative power of hematopoietic stem cells in ALS and may be a feasible treatment approach in the future.

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurological disease characterized by the progressive destruction of motor neurons, leading to disability and later death. There is no cure for the disease, and the only FDA-approved treatment (riluzole) adds only an additional few months of life to patients with ALS. Many factors are associated with the development of ALS, yet the exact causes of ALS development remain poorly understood.

Read More

Researchers Identify a Unique Marker for Bone Marrow Stem Cells

Jun 20, 2016 1:00:54 PM / by Karina Palomares posted in Bone Marrow, bone marrow-derived stem cells, hematopoietic stem cells


Stanford University scientists have identified a single marker that is only expressed in hematopoietic stem cells of the bone marrow.

Grounded in over a half of a century of research, the study of hematopoietic stem cells (HSCs) is one of the most exciting and rapidly advancing fields in medicine today. HSCs have great potential because of two cardinal properties: multipotency, defined as the ability to differentiate into all blood cell lineages, and long-term self-renewal, defined by the inexhaustible ability to produce daughter cells functionally identical to the parent upon cell division. Thus, HSC transplants have been routinely used to treat patients with malignant and non-malignant disorders of the blood and immune system.

Read More

Subscribe Here!

Posts by Topic

see all

Recent Posts